CinDome Pharma secures $40m to advance gastroparesis treatment

CinDome Pharma has secured $40m in a Series B financing extension round to develop deudomperidone for chronic gastroparesis.

May 19, 2024 - 04:00

CinDome Pharma secures $40m to advance gastroparesis treatment

CinDome Pharma has secured $40m in a Series B financing extension round to develop deudomperidone for chronic gastroparesis.

Read the original article

Tags:

Previous Article

FDA grants breakthrough therapy status for Nuvalent’s NVL-655

Moxifloxacin by Laboratorios Sophia for Bacterial Conjunctivitis: Likelihood of ...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

CohBar and Morphogenesis in merger for immuno-oncology therapies

CohBar and Morphogenesis in merger for immuno-oncology ...

May 24, 2023

U.S. backs study of safe injection sites, overdose prevention

U.S. backs study of safe injection sites, overdose prev...

May 9, 2023

STAT+: Biden invokes Defense Production Act to stem drug shortages

STAT+: Biden invokes Defense Production Act to stem dru...

Nov 29, 2023